Bicycle Therapeutics PLC (BCYC): Revenue
$72.59M
Year ended 2025-12-31
$61.20M
Trailing 12 months to 2026-06-30
+71.2%
3-year compound annual growth
+47.5%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $72.59M | +105.8% | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | $35.27M | +30.8% | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | $26.98M | +86.5% | 2026-03-17, From 2023-01-01 |
| 2022-12-31 | $14.46M | +23.6% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $11.70M | +12.6% | 2024-02-20, From 2021-01-01 |
| 2020-12-31 | $10.39M | -24.7% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $13.80M | +93.4% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $7.14M | +246.4% | 2021-03-11, From 2018-01-01 |
| 2017-12-31 | $2.06M | n/a | 2020-03-10, From 2017-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $72.59M | +105.8% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $72.30M | +153.5% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $70.85M | n/m |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $75.13M | +160.6% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $69.26M | -31.8% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $76.20M | -44.8% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $67.48M | +25.2% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $66.80M | +39.2% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $79.95M | +104.9% |
Compare BCYC, ASMB, VRDN, ABCL side by side · Screen every company in Pharmaceutical Preparations ↗